STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating
patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways
to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of
leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells